アジア太平洋地域のバイオインフォマティクスにおける AI 市場 – 2029 年までの業界動向と予測

アジア太平洋地域のバイオインフォマティクスにおける AI 市場の分析と規模

遺伝子配列決定コストの削減により、市場の需要が高まっています。より良い医療サービスを求める医療費の増加も、市場の成長に起因しています。主要な市場プレーヤーは、この重要な時期にさまざまなサービスの立ち上げとサービスの承認に重点を置いています。さらに、バイオインフォマティクスの需要の高まりと、バイオインフォマティクスに対する官民セクターの資金の増加も、市場の需要の高まりに貢献しています。

アジア太平洋地域のバイオインフォマティクスにおける AI 市場は、市場プレーヤーの増加と高度なサービスの利用可能性により、予測年度に成長しています。これに伴い、メーカーは市場で新しいサービスを開始するための研究開発活動に取り組んでいます。バイオインフォマティクス技術の進歩が市場の成長をさらに後押ししています。ただし、バイオインフォマティクスにおける計測機器の高コストとサイバーセキュリティの懸念により、予測期間中のアジア太平洋地域のバイオインフォマティクスにおける AI 市場の成長が妨げられる可能性があります。

Data Bridge Market Research の分析によると、バイオインフォマティクスにおける AI 市場は、予測期間中に 37.7% の CAGR で成長し、2029 年までに 47 億 4,088 万米ドルに達すると予想されています。バイオインフォマティクスにおけるハンドヘルド AI の使用を商業化する技術経路が急速に発展しているため、「サービス」がバイオインフォマティクスにおける AI 市場で最大の技術セグメントを占めています。バイオインフォマティクスにおける AI 市場レポートでは、価格分析、特許分析、技術の進歩についても詳細に取り上げています。         

Market Definition

Bioinformatics is a sub-discipline that has to do with the analysis of sequences of biological molecules. It usually refers to genes, DNA, RNA, or protein and is particularly useful in comparing genes, and other sequences in proteins and different sequences within an organism or between organisms, looking at the evolutionary relationships between organisms and using the patterns that exist across DNA and protein sequences to figure out what their function is.

Bioinformatics combines computer programming, big data, and molecular biology, which enables scientists to understand and identify patterns in biological data. It is particularly useful in studying genomes and DNA sequencing, as it allows scientists to organize large amounts of data.

From genetics to toxicology to mycology and radiobiology, there are scores of branches of biology to specialize in. And out of the many, bioinformatics is one of the intriguing fields which enables you to identify, evaluate, store, and retrieve biological information. Being an interdisciplinary field of study, it incorporates various applications of computer science, statistics, and biology to develop software applications for understanding biological data like DNA sequencing, protein analysis, evolutionary genetics, and others.

In the coming future, important decisions related to bioinformatics on drug discovery will be made by individuals who not only understand biology but can also use the bioinformatics tools and the knowledge they release to develop hypotheses and identify the quality target.

AI in Bioinformatics Market Dynamics

This section deals with understanding the market drivers, advantages, opportunities, restraints, and challenges. All of this is discussed in detail as below:

• Growing demand for bioinformatics

As genomics focused pharmacology continues to play a greater role in the treatment of various chronic diseases, especially cancer, next-generation sequencing (NGS) is evolving as a powerful tool for providing a deeper and more precise insight at the molecular underpinnings of individual tumors and specific receptors. Informatics is essential in biological research, which involves biologists who learn programming, computer programmers, mathematicians, or database managers to learn the foundations of biology.

• Reduction in the genetic sequencing cost

The strong demand for decreasing the cost of genomics and biomarker prediction has contributed to the creation of high-throughput genome sequencing, which often goes by the name next-generation sequencing (NGS). Thousands or millions of sequences in a single bioinformatics cycle are generated simultaneously. Dramatic upgrades to industrial NGS technologies have culminated in dramatic cutbacks in DNA sequencing cost-per-base. Thus recently, the main sequencing techniques have become the key subject of research, with sample design optimization taking a secondary function.

• Increasing public-private sector funding for bioinformatics

In order to improve the workflow for bioinformatics, the federal agencies, the public, and the private agencies are providing funds in order to carry out bioinformatics projects and to scientists for research purposes. It is important to approach possible funders with a clear proposal and strategy of what is to be achieved in terms of bioinformatics capacity building in the institution as well as the intended outputs and outcomes. Many government bodies and private organizations across the globe are increasingly investing in the field of bioinformatics. These investments have largely resulted in data and technological advancements in bioinformatics services, which in return, have improved the quality of these services.

• High cost of instrumentation

The cost of the device plays a major factor in the market. The AI based bioinformatics instrument is highly sophisticated, need high validation, and other specification increase. Genomics instruments are also equipped with advanced features and functionalities and are priced at a premium, ranging between USD 10–20 million. As pharmaceutical companies and research laboratories require many such systems, their capital expenditure on procuring multiple genomic instruments is very high. In the case of small and medium-sized pharmaceutical companies and research laboratories, it is not feasible for them to make such high investments in multiple genomics instruments. Hence, the high cost of AI based equipment is expected to restrain the market growth.

• Strategic initiatives of key players

The dramatic rise in the quality of research coupled with increasing research opportunities is because of various strategic initiatives taken by key market players. They are taking initiatives such as product launches, collaborations, mergers, acquisitions, and many more over the years and are expected to lead and create more opportunities in the market.

By successfully working with new technology firms to ensure continued growth, creativity, and viability in the industry, healthcare product suppliers have a huge opportunity. Health enterprises that implement technology-enabled technologies will explore new modes of goods for patient care, streamline processes, and engage patients more.

To discover and develop advanced bioinformatics products, companies are launching new initiatives, and collaborating with other key players to deliver more reliable results and services.

• Advancement in bioinformatics technology

The dimensions and cost of bioinformatics platforms and instruments are decreasing, allowing easier uptake by public health laboratories. Although currently, AI based bioinformatics requires highly specialized equipment and substantially skilled staff to analyze the data, it is unlikely that the bioinformatics revolution has finished. With rising technology upgradation of instruments and techniques is also needed, moreover, the bioinformatics market has a vast potential to upgrade in various applications, and there are high chances of the advancement of bioinformatics techniques in the forecasted period.

• Lack of skilled professionals to perform AI based bioinformatics technology

One of biology's most rapidly developing fields of study is bioinformatics, which involves the development and use of computational tools for the collection, archiving, organisation, analysis, and visualisation of biological data. The advancement of technology has made it possible to reach the level of next-generation analysis from conventional data analysis methods. The advancement of the technology of bioinformatics requires various skill sets for its handling. As the bioinformatics platforms are highly automated and costly machines, the improper handling of such machines can damage their parts which can hamper achieving analysis and visualisation of biological data. Thereby, it will proportionally hamper the result of data processing. The dearth of skilled professionals having adequate skills and knowledge to perform next-generation sequencing, therefore, hampers the growth of the market.

Post COVID-19 Impact on AI in Bioinformatics Market

During the pandemic, the bioinformatics sector is one that focused on using the combination of biology and information technology. At the heart of the industry is biological data, which is analyzed and transformed using IT techniques. Bioinformatics has always had huge potential when it comes to providing essential support to many areas of scientific research. The tools that bioinformatics can provide allow scientists to get to grips with larger data sets to mine and analyses them to discover crucial information that could lead to key discoveries. genetics and genomes have been the primary focus of bioinformatics in recent years, including comparative genomics, DNA microarrays, and functional genomics.

The growth of the AI in bioinformatics market is increasing with the growing demand for analysis tools in drug discovery and development and the integration of AI in various fields to interpret the data more conveniently. Hence, the market is expected to grow significantly in the forecast period, whereas the cost and the complexity of AI integration may hamper the market growth. The intervention of COVID-19 has increased the R&D activities, which in turn positively add to the market growth.

Recent Developments

• In June 2022, SOPHiA GENETICS, a leader in data-driven medicine, announced from the ESHG Conference in Vienna that it has achieved CE-IVD certification for the analytical functionality supported by its cloud-based SOPHiA DDM™ Platform, an accessory to diagnostic applications. With this certification, the SOPHiA DDM™ Platform is now IVD-ready to support all applications and modules designed for diagnostic purposes in the European Union and other markets recognizing this certification. This has helped the company to increase its Asia-Pacific presence in the market.
• In December 2021, JADBio and BioLizard announced their partnership. BioLizard is agile bioinformatics and AI/ML company Asia-Pacifically servicing clients in the life sciences, biotechnology, and pharmaceutical industries. JADBio is a robust automated machine learning platform that allows intuitive, timely, and interactive creation of ML predictive models on BioMedical and Multi-omics data while allowing for knowledge (biomarker signature) discovery through its vast range of reporting and analysis. This has helped the company to expand its products and services portfolio in the market.

Asia-Pacific AI in bioinformatics Market Scope

Asia-Pacific AI in bioinformatics market is segmented on the basis of offering, type, products and services, application, and sector. The growth amongst these segments will help you analyze major growth segments in the industries and provide the users with a valuable market overview and market insights to help them make strategic decisions for identifying core market applications.

Offering

• Services
•  Software
•  Others

On the basis of offering, the Asia-Pacific AI in bioinformatics market is segmented into services, software, and others.

Type

• Machine Learning
• Deep Learning
• Others

On the basis of type, the Asia-Pacific AI in bioinformatics market has been segmented into machine learning, deep learning, and others.

Products and Services

• Bioinformatics Services
• Bioinformatics Platforms
• Knowledge Management Tools

On the basis of products and services, the Asia-Pacific AI in bioinformatics market has been segmented into bioinformatics services, bioinformatics platforms, and knowledge management tools.

Application

• Genomics
• Chemoinformatics & Drug Design
• Proteomics
• DNA Sequencing
• System Biology
• Transcriptomics
• Text Mining
• Microarrays
• Metabolomics
• Others

アプリケーションに基づいて、アジア太平洋地域のバイオインフォマティクスにおける AI 市場は、ゲノミクス、ケモインフォマティクスと薬物設計、プロテオミクス、DNA シーケンシング、システム生物学、トランスクリプトミクス、テキストマイニング、マイクロアレイ、メタボロミクスなどに分類されています。

セクタ

• 医療バイオテクノロジー
• 動物バイオテクノロジー
• 植物バイオテクノロジー
• 環境バイオテクノロジー
• 法医学バイオテクノロジー
• その他

セクター別に見ると、アジア太平洋地域のバイオインフォマティクスにおける AI 市場は、医療バイオテクノロジー、動物バイオテクノロジー、植物バイオテクノロジー、環境バイオテクノロジー、法医学バイオテクノロジーなどに分類されています。

バイオインフォマティクス市場における AI の地域分析/洞察

バイオインフォマティクス市場における AI が分析され、市場規模の洞察と傾向が、上記の国、提供内容、タイプ、製品とサービス、アプリケーション、およびセクター別に提供されます。

アジア太平洋のバイオインフォマティクスにおける AI 市場レポートで取り上げられている国は、中国、韓国、日本、インド、オーストラリア、シンガポール、マレーシア、インドネシア、タイ、フィリピン、その他のアジア太平洋諸国です。中国は、創薬やゲノミクスなどのバイオインフォマティクスにおける高度な技術に対する需要の高まりにより、アジア太平洋のバイオインフォマティクスにおける AI 市場を支配すると予想されています。ただし、AI の理解とその開発の複雑さにより、予測期間中の市場の成長が妨げられると予想されます。

レポートの国別セクションでは、市場の現在および将来の傾向に影響を与える個別の市場影響要因と市場規制の変更も提供しています。下流および上流のバリュー チェーン分析、技術動向、ポーターの 5 つの力の分析、ケース スタディなどのデータ ポイントは、個々の国の市場シナリオを予測するために使用される指標の一部です。また、国別データの予測分析を提供する際には、アジア太平洋ブランドの存在と可用性、および地元および国内ブランドとの競争が激しいか少ないために直面​​する課題、国内関税の影響、貿易ルートも考慮されます。

中国は、AIの技術進歩の高まりと、さまざまな分野へのAIの統合の増加により、アジア太平洋のバイオインフォマティクスにおけるAI市場を支配すると予想されています。中国に続くのは、国内の技術進歩の高まりにより日本であり、韓国は、医薬品の発見と開発の需要の高まりと臨床試験の増加に起因しています。

バイオインフォマティクス市場シェア分析における競争環境と AI

バイオインフォマティクスにおける AI 市場の競争環境は、競合他社に関する詳細を提供します。含まれる詳細には、会社概要、会社の財務状況、収益、市場の可能性、研究開発への投資、新しい市場への取り組み、アジア太平洋地域でのプレゼンス、生産拠点と施設、生産能力、会社の強みと弱み、製品の発売、製品の幅と広さ、アプリケーションの優位性などがあります。提供されている上記のデータ ポイントは、バイオインフォマティクスにおける AI 市場への会社の重点にのみ関連しています。

バイオインフォマティクス市場における AI に携わる主要企業としては、SOPHiA GENETICS、Biomax Informatics Inc.、QIAGEN、NeoGenomics Laboratories、Eurofins Scientific、Illumina, Inc.、Thermo Fisher Scientific, Inc.、Strand Life Sciences、Dassault Systèmes、SomaLogic Operating Co., Inc.、Elucidata などが挙げられます。

SKU-69030